Prognosis
CDC Advisers Reaffirm Backing of J&J’s Vaccine After Pause
- Panel reviewed 15 cases of rare, severe blood clots in women
- Agencies could decide to resume shot’s use as soon as Friday
This article is for subscribers only.
A panel of medical experts reaffirmed their support for Johnson & Johnson’s Covid-19 vaccine, setting the stage for regulators to allow use of the shot to resume after a pause to study rare, severe blood clots in some recipients.
The Advisory Committee on Immunization Practices voted 10 to 4, with one abstention, to back the vaccine, opening the way for the U.S. Centers for Disease Control and Prevention and the Food and Drug Administration to lift the hold on the shot. Regulators put dosing on hold 10 days ago to gather more information about the side effect.